EGFR and non-small cell lung carcinoma: After adjustment, afatinib showed lower risk of treatment failure compared with gefitinib (HR 0.54, 95% CI 0.41–0.71, P < 0.001) and erlotinib (HR 0.62, 95% CI 0.46–0.83, P = 0.001) in NSCLC patients with EGFR-activating mutations.